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AbsTrACT
background rolandic epilepsy (re) is the most 
common genetic childhood epilepsy, consisting of focal, 
nocturnal seizures and frequent neurodevelopmental 
impairments in speech, language, literacy and attention. 
a complex genetic aetiology is presumed in most, with 
monogenic mutations in GRIN2A accounting for >5% of 
cases.
Objective to identify rare, causal cnV in patients with 
re.
Methods We used high-density SnP arrays to analyse 
the presence of rare cnVs in 186 patients with re from 
the UK, the USa, Sardinia, argentina and Kerala, india.
results We identified 84 patients with one or more rare 
cnVs, and, within this group, 14 (7.5%) with recurrent 
risk factor cnVs and 15 (8.0%) with likely pathogenic 
cnVs. nine patients carried recurrent hotspot cnVs 
including at 16p13.11 and 1p36, with the most striking 
finding that four individuals (three from Sardinia) carried 
a duplication, and one a deletion, at Xp22.31. Five 
patients with re carried a rare cnV that disrupted genes 
associated with other epilepsies (KCTD7, ARHGEF15, 
CACNA2D1, GRIN2A and ARHGEF4), and 17 cases 
carried cnVs that disrupted genes associated with other 
neurological conditions or that are involved in neuronal 
signalling/development. network analysis of disrupted 
genes with high brain expression identified significant 
enrichment in pathways of the cholinergic synapse, 
guanine-exchange factor activation and the mammalian 
target of rapamycin.
Conclusion Our results provide a cnV profile of 
an ethnically diverse cohort of patients with re, 
uncovering new areas of research focus, and emphasise 
the importance of studying non-western european 
populations in oligogenic disorders to uncover a full 
picture of risk variation.
INTrOduCTION
With an incidence of 1/2500, rolandic epilepsy 
(RE) or benign epilepsy with centrotemporal spikes 
(MIM:117100) is the most common genetic child-
hood epilepsy.1 2 Children experience focal seizures 
usually in sleep that affect the vocal tract, with 
sensorimotor symptoms that progress to the tongue, 
mouth and face, resulting in hypersalivation and 
speech arrest. The characteristic EEG abnormality 
is blunt centrotemporal spikes (CTS) typically with 
frontal positivity and sleep activation. RE starts 
at a mean of 7 years, and there is a spontaneous 
remission of seizures during adolescence.3 4 Neuro-
developmental comorbidities such as speech sound 
disorder, language impairment, reading disability, 
migraine and attention impairment are common 
both in children with RE and their families5–7; 
however, the prognosis for these conditions is less 
clear.
The underlying genetic basis of RE is still 
largely unknown. Both an autosomal-dominant 
model of inheritance of the EEG trait CTS8 and 
a complex mode of inheritance for seizure risk9 
have been suggested. Loci for CTS have been iden-
tified at ELP4-PAX6 on 11p1310 11 and at 15q13 
(CHRNA7).12 Independent replication of ELP4 
SNP association with CTS was not achieved.13 
However, it has subsequently been shown that it 
is variation at a micro-RNA seed region within the 
3′ untranslated region of PAX6 which increases the 
risk of CTS.14 Rare mutations in RE cases, with and 
without neonatal convulsions, were first found in 
potassium channels KCNQ2 and KCNQ3.15 With 
the advent of large-scale exome sequencing, muta-
tions in five further genes are now shown to be 
rare risk factors; the NMDA receptor GRIN2A; 
neuronal splicing regulators RBFOX1 and RBFOX3; 
GABRG2—a gamma-aminobutyric acid (GABA) 
type A receptor; and a repressor of the mammalian 
target of rapamycin (mTOR) complex 1 signalling 
pathway, DEPDC5.16–21
CNV is a well-known risk factor in both 
generalised and focal epilepsies, and is also an 
important cause of epileptic encephalopathies 
(EE).22–24 Both recurrent ‘hotspot’ and rare inher-
ited and de novo CNVs are beginning to explain 
the diverse phenotypes in individual families 
and across disorders, suggesting a shared molec-
ular basis for several phenotypes. Children with 
EEs that form part of the epilepsy-aphasia spec-
trum (of which RE is at the mild end), namely 
Landau-Kleffner syndrome (LKS) and continuous 
spike and waves during slow wave sleep (CSWS), 
carry a heterogeneous mixture of rare CNVs, with 
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enrichment for cell adhesion genes associated with autism and 
language impairment.25 In a small study of 47 patients with 
either typical or EEG-atypical RE, half carried rare microdele-
tions and microduplications, some disrupting known causal 
genes for epilepsy. Two patients in this study with atypical RE 
also carried the 16p11.2 recurrent duplication.26 Motivated 
by this finding, Reinthaler et al undertook a screening of six 
recurrent CNVs in patients with typical RE and LKS/CSWS/
atypical benign partial epilepsy ABPE.27 1.2% of those with 
RE, and one with LKS, carried the 600 kb 16p11.2 duplica-
tion, and one a 110 kb duplication, which was in significant 
excess compared with controls.
These studies prompted us to carry out a genome-wide inves-
tigation of CNV in a large cohort of well-phenotyped, typically 
presenting patients with RE. We report the presence of both a 
large number of causal and potentially causal heterogeneous, 
rare CNVs, as well as recurrent hotspot CNVs in these patients. 
The most prominent findings are of recurrent duplications and 
one deletion at Xp22.31, and the network clustering of genes 
involved in cholinergic synapses and guanine-exchange factor 
activation.
MeThOds
study participants
Five groups of patients with typical RE at presentation from 
different genetic backgrounds (total n=195) were included 
in this study from the UK (n=41), the USA (n=52), Sardinia 
(n=62), Kerala, India (n=34), and Argentina (n=6). We also 
analysed 70 ethnically matched control subjects from Kerala. 
Written informed consent was obtained from all participating 
families, both parents and, where appropriate, children/adoles-
cents. All respective local institutional review boards approved 
the study. In total, 800 control individuals for the network anal-
ysis, called NL4, were matched for gender and ethnicity (see 
below) to the European cases from a population-based study in 
the Netherlands. Ascertainment and ethical considerations are 
found in refs.28 29
Case ascertainment and definition
RE probands and their families were prospectively recruited for 
genetic studies from the US paediatric neurology centres in New 
York, New Jersey, Pennsylvania, Connecticut, Rhode Island and 
Massachusetts; from southeastern UK paediatric centres; from 
the Epilepsy Unit at the Pediatric Hospital, Cagliari Sardinia; 
from Sree Chitra Institute for Medical Science and Technology, 
Kerala; and from the Department of Neurology, Hospital de Pedi-
atría Prof. Dr. J.P. Garrahan, Buenos Aires, Argentina. Ascertain-
ment was through the proband. RE cases were enrolled if they 
met stringent eligibility criteria of at least one witnessed seizure 
with typical features: nocturnal, simple partial seizures affecting 
one side of the body, or on alternate sides; oro-facial-pharyngeal 
sensorimotor symptoms, with speech arrest and hypersalivation; 
age of onset between 3 and 12 years; no previous epilepsy type; 
normal global developmental milestones; normal neurological 
examination; at least one interictal EEG with centrotemporal 
sharp waves and normal background; and neuroimaging (if 
performed) that excluded an alternative structural, inflamma-
tory or metabolic cause for the seizures. All participants were 
evaluated by a physician for associated clinical features. We cate-
gorised seizure number into low (<10 lifetime seizures) and high 
(≥10 lifetime seizures); and antiepileptic drugs  (AEDs) used as 
zero or monotherapy versus two or more.
Genotyping and CNV detection
We used high-density SNP genotyping arrays to detect the pres-
ence of CNVs from genomic DNA: HumanOmniExpress-12 for 
all the RE cases and Indian controls, and HumanCoreExome-12 
V.1-0 for the UK family members as well as the UK cases, which 
were therefore typed on both arrays (Illumina, USA). NL4 
controls were also genotyped on the HumanOmniExpress-12 as 
detailed in ref.30 Arrays were processed according to the manu-
facturer’s instructions. To minimise false positives, CNVs were 
called using both the PennCNV software31 and the Nexus Copy 
Number package (BioDiscovery, USA) from signal intensity data 
after preprocessing in Illumina GenomeStudio Software. For 
PennCNV, a GC model file was incorporated into the analysis to 
correct for GC-rich regions that cause genomic waves in signal 
intensities. The  clean_ cnv. pl script (https:// github. com/ WGLab/ 
PennCNV/ blob/ master/ clean_ cnv. pl) was also run to merge adja-
cent CNVs with a gap <20% of the total merged length. The 
sample-level quality control (QC) criteria used for PennCNV 
were SD for autosomal log R ratio >0.26, B allele frequency 
drift  of >0.003, waviness  factor −0.05  to  0.05,  and  samples 
with more than45 CNVs were removed. Cut-offs for CNV calls 
in PennCNV were for variants that contained >15 consecu-
tive altered SNP probes and were >20 kb in size. In the Nexus 
software, systematic array correction files were used for the 
two different arrays to correct for GC bias, and a significance 
threshold of 1×10–7 was applied. The SNP-FAST2 Segmentation 
algorithm was used for analysis, with homozygous frequency 
threshold at 0.95, hemizygous loss threshold at −0.23 and single 
copy gain at 0.13 for the log R ratio. Nine samples were removed 
from the project because they had a <95% call rate, a probe to 
probe variability (quality score) of >0.2 or a gender mismatch, 
leaving n=186. Cut-offs for CNV calls were the same as for 
PennCNV. CNVs were only taken forward to the next stage of 
analysis if they were called from both software approaches and, 
for UK samples, if they were called from both array types. CNVs 
showing >90% overlap with variants of a frequency of ≥0.1% 
of the same type, reported in the Database of Genomic Vari-
ants (http:// projects. tcag. ca/ variation/), were considered copy 
number polymorphisms and were excluded from further anal-
ysis, therefore CNVs analysed here are designated as ‘rare’.
Validation of CNVs
We validated CNVs for the UK cases using the Illumina Human-
CoreExome-12 chip. Validation for other cases/family members 
was performed with real-time quantitative PCR (qPCR) using 
the Qiagen (USA) Type-it CNV Syber Green Kit according to the 
manufacturer’s instructions and as in ref.32 The ΔΔCT method 
of relative quantification was used, and the ratio (R) of the 
copy number change of the gene of interest in the case sample 
compared with the control sample calculated using R=2-ΔΔCT.
QC for ethnicity matching
A QC was performed separately on both case/family and NL4 
control datasets, according to methods previously published.30 
Both datasets were tested for the presence of related and dupli-
cated samples (pi-hat >0.1). After the QC, the case and control 
datasets were merged with the HapMap3 dataset and the first 
four principal components (PCs) were calculated using the 
EIGENSTRAT method. Individuals of non-European ancestry 
that scattered >10 SD from the HapMap CEU mean, consid-
ering the first four PCs, were removed. After the removal of 
population outliers, PCs were calculated on an LD-pruned set 
of SNPs, considering only genotype data from the case and NL4 
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datasets (MAF cut-off >0.011, based on ref.33). Outliers were 
removed considering a deviation from the stratum mean of the 
first four PCs of >5 SD (online supplementary tables S1 and S2, 
and supplementary figure S1).
Network analysis
Network analysis was used to identify if the genes disrupted by 
the RE CNVs are enriched for certain types of biological func-
tion and to identify other genes and pathways that may interact 
with the disrupted RE genes, giving ideas about potential new 
avenues of understanding for the disorder. To identify interac-
tion partners, separate gene networks were created in Ingenuity 
Pathway Analysis (IPA, Qiagen Bioinformatics, Denmark) of 
CNV disrupted genes with high brain expression from the Euro-
pean ancestry cases or controls. IPA constraints were to include 
direct and indirect relationships, 70 genes within the network, 
only experimentally observed data and only endogenous 
mammalian node types. To identify CNV disrupted genes with 
high brain expression, we used the BrainSpan database34 avail-
able from http://www. brainspan. org/ static/ download. html and 
genes with average log2 RPKM >4.5 (the top 18%). The genes 
formed within the IPA network were then used as an input for 
the enrichment and functional annotation tool Enrichr35 (http:// 
amp. pharm. mssm. edu/ Enrichr/). Enrichr was used to identify 
KEGG pathways and GO terms that had significant enrichment 
(p<0.05, adjusted for the number of tests for the category type). 
Enrichr carries out computational analysis of the input sets by 
comparing them to these annotated gene sets representing prior 
biological knowledge.
In order to identify potential physical connectivity between 
proteins, a list of all of the genes from the rare CNVs identified in 
RE patients was uploaded to the Disease Association Protein-Pro-
tein Link Evaluator (DAPPLE) V.0.17 within GenePatten 
(https:// genepattern. broadinstitute. org/ gp).36 DAPPLE extracts 
seed genes from the uploaded gene list and converts them into 
proteins which are found in the InWeb database of high-confi-
dence protein–protein interactions. Also, 1000 random networks 
were generated by permutation to assess if the connectivity of 
each seed protein with the reference protein–protein interaction 
network was greater than expected by chance. The most highly 
enriched genes (corrected p<0.05) were uploaded to IPA for 
network analysis using the settings as above.
resulTs
We studied genome-wide CNV content in a cohort of 186 
unrelated patients with RE using high-density SNP genotyping 
arrays. The patients were from diverse genetic backgrounds; 
from the UK (n=41), the USA (n=49), Sardinia (n=58), Kerala, 
India (n=32), and Argentina (n=6), which allowed us to identify 
additional variants that may differ from those common in main-
land European populations. We identified 84 patients (45%) 
with one or more rare CNVs (frequency <0.1% in control popu-
lations from the Database of Genomic Variants (http:// projects. 
tcag. ca/ variation/), as well as unreported in 70 Kerala controls): 
14 carried CNVs that are recurrent risk factors (7.5%), table 1, 
and 15 carried CNVs that were likely pathogenic (8.0%), a total 
n=28, because two patients carried both a pathogenic and a 
likely pathogenic CNV (table 2). These CNVs were confirmed 
by qPCR or analysis of ExomeChip data. The manual assigna-
tion of potential pathogenicity was based on gene content (exons 
were always disrupted), CNV size, segregation with disease or de 
novo occurrence, and previous literature on epilepsy and related 
neurological disorders. The remaining 56/84 participants carried 
rare CNVs that were of uncertain clinical significance. The mean 
rare CNV length was 305 kb and median length 155 kb. Also, 10 
out of the 14 carriers of risk factor CNVs were female, compared 
with 35% of the overall cohort. Inheritance could be assessed in 
most patients from the UK and US cohorts due to the availability 
of parental DNA (online supplementary figure S2).
hotspot CNVs
Pathogenic CNVs classified as a risk factor for RE include those 
that are ‘hotspots’—regions of the genome that contain large 
segmental duplications, allowing non-allelic homologous recom-
bination during cell division. Nine patients carried hotspot 
CNVs, with the most striking finding that four individuals 
carried a duplication and one a deletion at Xp22.31 (figure 1). 
Three duplications and one deletion were at the most frequent 
breakpoints (6.44–8.14 Mb) and one duplication had a more 
distal start (7.49–8.14 Mb).
Other hotspot CNVs included a deletion at 16p13.11 and 
a deletion of the distal 1p36 region, containing the candidate 
gene KLHL17.37 Two further individuals carried duplications of 
the 1q21 hotspot. We could assess inheritance for three patients 
carrying hotspot CNVs (online supplementary figure S2); 
16p13.11 deletion occurred de novo in patient 1012-301, as did 
the Xp22.31 deletion in 1052-301. The Xp22.31 duplication in 
1039-301 was inherited from his unaffected mother.
rare CNVs
Nineteen patients with RE (ie, those from tables 1 and 2 that 
do not carry hotspot CNVs described earlier, apart from one 
patient that had both a hotspot and rare CNV) were found to 
either carry a rare CNV that disrupted genes that are recurrent 
risk factors for epilepsy (n=5, disrupting GRIN2A, KCTD7, 
ARHGEF15, CACNA2D1 and ARHGEF4) (table 1), genes that 
are associated with other neurological conditions or that are 
involved in neuronal signalling and/or development (table 2). We 
could assess inheritance and family segregation of these CNVs 
in 12 of the 19 patients (tables 1 and 2, online supplementary 
figure S2). Two of the CNVs occurred de novo, and 10 were 
inherited from a parent (two in one patient from the mother), 
sometimes with a family history of epilepsy or neurodevelop-
mental disorders.
Network analysis
To identify interaction partners and potential new pathways 
disrupted in RE, we created gene networks with IPA using as 
input the CNV-disrupted genes with high brain expression from 
the European ancestry cases versus European controls. The top 
network generated for each dataset (now including genes not 
within the CNVs) was input into the Enrichr enrichment anno-
tation tool to identify biological meaning, including enrichment 
for functional terms.35 Enrichr uses a modified Fisher’s exact 
test to calculate if the genes from the network are found more 
frequently within a gene set library (Gene Ontology) or pathway 
(KEGG) than the random chance across the genome for that 
category. It uses the Benjamini-Hochberg false discovery rate 
to correct for multiple hypotheses. For the European cases, the 
KEGG pathway of cholinergic synapse was significantly enriched 
PAdj=9.6×10
−7, and the GABAergic synapse, PAdj=6.2×10
−  4 
(online supplementary figures S3 and S4, and table S4). GO 
molecular function terms were enriched for GTPase and rho 
guanyl-exchange factor activation, and biological process terms 
for the positive regulation of apoptotic processes and protein 
phosphorylation cascades (online supplementary tables S5 and 
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S6). For the controls, no KEGG pathway was enriched, and the 
only enriched GO terms were molecular function terms that are 
involved in mRNA and small RNA binding (online supplemen-
tary table S7).
In order to identify significant protein interaction networks 
that modulate disease risk encoded by disrupted genes identi-
fied from all of the patients with RE, we applied DAPPLE.36 
This tool extracted ‘seed genes’ from the 279 genes in the CNVs 
using the InWeb database of high-confidence protein–protein 
interactions. Ten had highly enriched connectivity (p<0.01 
corrected for multiple testing over random network genera-
tion): REG1A, CTNNA3, DLG2*, HIBCH, ABCC6, CTNNA2*, 
KLHL17, RPL9*, NEIL2* and NOC2L*. Five of these genes also 
show high expression in the brain, indicated with an asterisk. A 
further 26 genes (12 with high brain expression) had corrected 
p values<0.05. An IPA network formed using these 36 genes as 
input, but allowed to expand to 70 genes on network formation 
to identify interaction partners (figure 2) contained three hubs 
not found within the CNVs themselves. Two hubs, AKT1/2/3 
part of the mTOR pathway (mutated in focal cortical dysplasia38) 
and ERK1/2 (also known as MAP kinases 1 and 2), are important 
regulators of synaptic excitability involved in epilepsy in animal 
models and human disease.39 Six other genes within the network, 
not found in these RE CNVs, are also epilepsy candidates, indi-
cating the strength of this approach for finding disrupted gene 
pathways (figure 2).
Phenotypic correlates
We used two-tailed Fisher’s exact tests for comparison of propor-
tions to analyse the association between the presence of a risk 
factor or potential risk factor CNV, and either seizure frequency 
or need for multiple AEDs (table 3). Our results show that the 
presence of a risk factor or potential risk factor CNV is not asso-
ciated with high seizure number (>10 lifetime seizures), p=0.3, 
nor the need for multiple AEDs, p=0.07.
dIsCussION
From this large investigation of genome-wide CNV in children 
with RE, we identified both recurrent and rare heterogeneous 
CNVs that contain genes involved in synapse formation, neuronal 
excitability and synaptic plasticity, axon guidance and neuronal 
development. Four patients with RE carried CNVs that disrupted 
genes known to cause other epilepsies; KCTD7, ARHGEF4, 
ARHGEF15 and CACNA2D1, expanding the phenotypes asso-
ciated with these genes. One individual was also found with a 
breakpoint within the known risk factor  gene GRIN2A.16–18 
These, and other pathogenic CNVs, were not associated with 
seizure number or AED use variables, suggesting that they do not 
generally result in more severe phenotypes.
The genetic model of RE remains complex: including our data, 
both exome sequencing and CNV analysis, has identified only 
a small amount of the overall genetic risk. The heterogeneous 
nature of RE is underpinned by our study, where only variation 
at Xp22.31 is recurrent. Out of the 30 rare CNVs identified in 
patients with RE by Dimassi, only two overlap with our larger 
cohort; we both identified one patient with a maternally inher-
ited deletion of part of UNC13C, and we identified a de novo 
deletion of the 16p13.11 hotspot, whereas Dimassi identified a 
maternally inherited duplication of the same region.26 A hetero-
geneous mixture of CNVs has also been identified in a cohort of 
patients with LKS and CSWS17, which form the severe end of 
the epilepsy-aphasia spectrum, with RE at the mild end. These 
CNVs, as here in RE, often contain genes associated with other 
neurodevelopmental disorders such as ASD and LI, especially 
cell adhesion proteins, strengthening the aetiological overlaps 
between these disorders.
We have identified both de novo and inherited CNVs, with 
several unaffected carrier parents, reflecting the incomplete 
penetrance that is common in the genetic epilepsies.23 Indeed, 
for other genetic variants associated with RE such as mutations in 
GRIN2A, GABRG2 and DEPDC5, as well as for 16p11.2 dupli-
cations, incomplete penetrance is commonly noted.16–20 27 This 
might partly be because mild phenotypes presenting in childhood 
Figure 1 Breakpoints of 5 cases with Xp22.31 hotspot cnVs in our rolandic epilepsy (re) case series, 2 cases with re and Xp22.31 cnVs from the 
literature and 19 further cases with epilepsy or seizures form the literature. individual iDs or publication references are shown to the left and references 
are in online supplementary table 3. Blue lines indicate duplications and red lines deletions. gene positions are shown above the cnVs. Positions of 
segmental duplication sequence (locus control regions) are shown in the middle of the figure with grey bars. From http://genome.ucsc.edu/, hg19 
assembly. UcSc, University of california, Santa cruz.
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in earlier generations, such as a single seizure or early difficul-
ties with speech and language may have been forgotten and not 
reported. In some of these families it is likely that additional, and 
as yet largely unknown, genetic factors contribute to the risk of 
developing RE. Indeed, two genetic ‘hits’ are not an uncommon 
observation in RE. In our study, we identified four patients 
carrying two rare risk factor CNVs, Dimassi et al described 10/47 
patients with two rare CNVs26 and Reinthaler et al27 identified 
1 patient with RE carrying two hotspot CNVs and 1 family with 
a de novo 16p11.2 duplication and an inherited DEPDC5 muta-
tion. In a further study, one patient with RE was found to carry 
a de novo GABRG2 mutation as well as an inherited GRIN2A 
mutation, and a second a paternally inherited 15q11.2 duplica-
tion and a maternally inherited GABRG2 mutation. Candidate 
gene or exome sequencing of the cohort described in this paper 
may therefore allow identification of further second hits.
One of the most striking findings of the study is an enrichment 
of CNV at the Xp22.31 locus in five patients with RE compared 
with previous reports.24 27 Contiguous gene syndromes have 
long been associated with microdeletions at Xp22.31, the 
phenotypic nature of which depends on the genes encom-
passed.40 Common phenotypes in those with CNV at Xp22.31 
are mental retardation, developmental delay and ichthyosis, 
with seizures and epilepsy less frequently reported. However, a 
recent paper has observed epilepsy in 24% of paediatric cases.24 
Locus control regions (long-range cis-regulatory elements) espe-
cially at the distal ends of VCX3A and VCX2 predispose this 
region to non-alleleic homologous recombination (figure 1).41 
Genes in the most commonly disrupted region of Xp22.31 
(figure 1) are VCX3A, which may contribute to mental retar-
dation42; HDHD1, a phosphatase involved in dephosphoryla-
tion of a modified RNA nucleotide43; STS, encoding a steroid 
sulfatase which hydrolyses neurosteroids that affect membrane 
potential and current conductance of the neuron, controlling 
network excitability and seizure susceptibility; VCX, which 
regulates mRNA translation and neurite outgrowth44; PNPLA4, 
which plays a key role in triglyceride hydrolysis and energy 
metabolism; and VCX2, which is not yet well characterised. 
Thus, there are several genes in the region which could poten-
tially contribute individually, or in an interacting model, to the 
seizure and neurodevelopmental profile of RE. The differing 
size and location of smaller CNVs identified in other publi-
cations that disrupt only one or two of the genes at Xp22.31 
indicates a minimum common region cannot be identified to 
account for the seizure phenotype, and other factors may also 
be required. Therefore, while a definitive molecular aetiology 
cannot be provided at this stage, the addition of five cases with 
RE expands on the seizure phenotypes associated with the 
Xp22.31 region, especially in Sardinian patients.
Figure 2 network created by ingenuity Pathway analysis using the top 36 most highly connected genes disrupted by rolandic epilepsy (re) cnVs as 
assessed by the Disease association Protein-Protein link evaluator.36 Orange indicates a gene within a cnV, pink a hub gene, green an epilepsy-associated 
gene not found within a cnV and white are genes added by ingenuity Pathway analysis during network generation due to direct physical or indirect (eg, via 
activation) interactions with the input list.
Table 3 Numbers of patients with rolandic epilepsy within different 
seizure and antiepileptic drug (AED) categories
Patients with no 
risk/potential 
risk factor 
CNVs (n)
Patients with risk 
or potential risk 
factor CNVs (n) Total P values
<10 lifetime seizures 97 14 111 0.3
>10 lifetime seizures 52 12 64
0–1 AED 108 14 122 0.07
≥2 AEDs 43 13 56
(Eleven patients are missing seizure frequency and eight missing AED data).
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It is of note that we did not observe any duplications at the 
16p11.2 locus previously reported in around 1% of patients with 
RE26 27 (although the two patients reported in ref.26 had atypical 
RE). However, only one Xp22.31 duplication was reported in 
these two previous cohorts. This could indicate that the differing 
genetic backgrounds of the participants may play a role in the 
contrasting enrichment patterns. The three ‘typical breakpoint’ 
deletion patients at Xp22.31 described here are unrelated 
Sardinians. Sardinia is more isolated genetically than other 
parts of the Mediterranean, and may constitute a pre-Indo-Eu-
ropean population. However, there is also substantial heteroge-
neity within Sardinia itself due to its internal geography. The 
population of southern Sardinia appears to cluster somewhat 
with European populations with regard to allele distributions, 
whereas that of northern Sardinia is highly differentiated and 
determined by contributions of several ethnic groups, potentially 
including northern African and Middle Eastern origins.45 Thus 
our work highlights the importance of studying populations with 
different genetic backgrounds to fully identify the risk factors in 
oligogenic disorders such as RE. We also did not find deletions at 
15q13.3 or 15q11.2 and only one deletion at 16p13.11. These 
hotspot rearrangements have been associated with genetic gener-
alised epilepsies (GGEs), but not with genetic focal epilepsies, a 
distinction that is further strengthened here.22 46 47
Network analysis of the RE CNV genes identified several inter-
esting pathways that may indicate new risk factors (cholinergic 
synapse, guanine exchange factors) and give further strength 
to those already implicated (mTOR pathway, MAP kinases). 
Acetylcholine (ACh) acts as a neuromodulator within the brain, 
causing changes in neuronal excitability and synaptic plasticity, 
altering release of neurotransmitters and coordinating the firing 
of groups of neurons.48 The enrichment for brain expressed 
genes within cholinergic synapses introduces the regulation of 
ACh signalling as a potential new pathogenic pathway. Indeed, 
fluctuating levels of ACh during different sleep states correlate 
with periods of increased seizure susceptibility.49 Alterations to 
both presynaptic and postsynaptic responses to ACh, as seen 
here, may influence network excitability at these critical time 
points during sleep in patients with RE. This theory will now 
require further work in both cellular and animal models, and 
correlations with patient sleep EEG for confirmation.
Genes with high brain expression and those that stimulate the 
exchange of GDP for GTP, guanine nucleotide exchange factors, 
(GEFs), to activate GTPases, were also significantly enriched 
in European cases. GEFs regulate many aspects of cytoskel-
etal organisation, such as the morphogenesis and plasticity of 
dendritic spines and the induction of long-term potentiation, as 
well as vesicle transport and the regulation of excitatory synapse 
development. Indeed, GEFs have already been implicated in 
learning disability with epilepsy50 and shown to have function-al-
tering mutations in epileptic encephalopathy,51 52 indicating their 
potential importance as an avenue to explore in RE causality.
We were limited in our study by the low number of matched 
controls from the Kerala region, which meant we were not able 
to carry out a case–control analysis for this cohort. However, we 
have reported the CNVs descriptively if they were not present 
in the matched controls or other databases. Another limitation 
is that we did not have parental DNA for many of the RE cases 
to assess CNV inheritance. This would have aided in the puta-
tive assignment of pathogenicity, as those that arise de novo, or 
segregate with affectedness, would more likely predispose to the 
epilepsy.
In summary, we show that rare CNVs may play a pathogenic 
role in a significant proportion of children with RE, although 
the model of genetic risk still requires elucidation. Network 
analysis of genes with high brain expression from this ethnically 
diverse cohort suggests the involvement of new molecular path-
ways in rolandic epilepsy. The prevalence and nature of recur-
rent CNVs in RE can differ by population, but also clearly differ 
from those involved in GGEs. Aside from a few rare monogenic 
cases, it is likely that the majority of RE is explained by interac-
tions between sequence and CNV, and this hypothesis could be 
addressed in future large-scale studies.
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